Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Suxamethonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.95 |
| ▸ | BLM | P54132 | 1/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.91 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.91 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.61 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.60 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | PGR | P06401 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.60 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Suxamethonium SCHEMBL20815392 | 1.00 | MAPT (0.95) | MAPTBLMADRA2AADRA1ACHRM5 | |
| Suxamethonium SCHEMBL41536 | 0.98 | MAPT (1.00) | MAPTBLMADRA2AADRA1ACHRM5 | |
| Suxamethonium SCHEMBL41537 | 0.95 | ADRA2A (1.00) | MAPTBLMADRA2AADRA1ACHRM5 | |
| Suxamethonium SCHEMBL2690356 | 0.93 | ADRA2A (0.95) | MAPTBLMADRA2AADRA1ACHRM5 | |
| Suxamethonium SCHEMBL21356923 | 0.93 | ADRA2A (0.95) | MAPTBLMADRA2AADRA1ACHRM5 | |
| Suxamethonium SCHEMBL1643328 | 0.93 | ADRA2A (0.95) | MAPTBLMADRA2AADRA1ACHRM5 | |
| Suxamethonium SCHEMBL2821312 | 0.93 | ADRA2A (0.95) | MAPTBLMADRA2AADRA1ACHRM5 | |
| Suxamethonium SCHEMBL16320883 | 0.93 | ADRA2A (0.95) | MAPTBLMADRA2AADRA1ACHRM5 | |
| Hydrochloric Acid SCHEMBL25376349 | 0.89 | MAPT (0.83) | MAPTBLMADRA2AADRA1ACHRM5 | |
| Hydrochloric Acid SCHEMBL28824833 | 0.89 | MAPT (0.83) | MAPTBLMADRA2AADRA1ACHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116234581-A | Succinylcholine composition and medicine-carrying syringe thereof | 阿奎坦实验室 | 2023-06-06 | — | — | CN | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| EP-2905361-B1 | METHOD OF FORMING A METAL COATING | TOYOTA MOTOR CO LTD (JP) | 2022-01-05 | — | — | EP | disclosed |
| EP-3639855-A1 | COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT | The Doshisha (JP) | 2020-04-22 | — | — | EP | disclosed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| CN-104818513-B | Electroplating pool and metal coating and forming method thereof | 丰田自动车株式会社 | 2017-08-18 | — | — | CN | disclosed |
| US-9708723-B2 | Electroplating cell, and metal coating and method of forming the same | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2017-07-18 | — | — | US | disclosed |
| EP-2905361-A1 | ELECTROPLATING CELL, METAL COATING AND METHOD OF FORMING THE SAME | Toyota Jidosha Kabushiki Kaisha (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-20150218723-A1 | ELECTROPLATING CELL, AND METAL COATING AND METHOD OF FORMING THE SAME | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2015-08-06 | — | — | US | disclosed |
| WO-2014024207-A1 | PROCESS FOR PREPARATION OF SUCCINYLCHOLINE CHLORIDE | NEON LABORATORIES LTD. (IN) | 2014-02-13 | — | — | WO | disclosed |
| US-20110151022-A1 | THIOTUNGSTATE ANALOGUES AND USES THEREOF | ATTENUON, LLC | 2011-06-23 | — | — | US | disclosed |
| US-7851505-B2 | Thiotungstate analogues and uses thereof | ATTENUON, LLC (US) | 2010-12-14 | — | — | US | disclosed |
| CN-100558409-C | Thiotungstate analogues and uses thereof | ATTENUON LLC (US) | 2009-11-11 | — | — | CN | disclosed |
| EP-1633310-A4 | THIOTUNGSTATE ANALOGUES AND USES THEREOF | ATTENUON LLC (US) | 2006-10-18 | — | — | EP | disclosed |
| CN-1832761-A | Thiotungstate analogs and uses thereof | ATTENUON LLC (US) | 2006-09-13 | — | — | CN | disclosed |
| US-20060160805-A1 | for the treatment of diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or nuclear factor kappa beta dysregulation | ATTENUON, LLC | 2006-07-20 | — | — | US | disclosed |
| EP-1633310-A2 | THIOTUNGSTATE ANALOGUES AND USES THEREOF | Attenuon, LLC (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004110364-A9 | THIOTUNGSTATE ANALOGUES AND USES THEREOF | ATTENUON L L C (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2004110364-A2 | THIOTUNGSTATE ANALOGUES AND USES THEREOF | ATTENUON L.L.C. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160805-A1 | for the treatment of diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or nuclear factor kappa beta dysregulation | NFKBIA, RELA, IKBKG | MAPT 64/4885BLM 4837/4885ADRA2A 3534/4885 |
| US-20110151022-A1 | THIOTUNGSTATE ANALOGUES AND USES THEREOF | NFKBIA, RELA, SLC40A1 | MAPT 59/4885BLM 4662/4885ADRA2A 4435/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | MAPT 4184/4885BLM 2264/4885ADRA2A 4514/4885 |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | HDGF, F11, F12 | MAPT 4184/4885BLM 2264/4885ADRA2A 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.